Development of a Multimodal Index to Improve the Predictive Value of Success in Weaning From Mechanical Ventilation
Launched by CORPORACION PARC TAULI · Sep 13, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how to improve the process of weaning patients off mechanical ventilation, which is a machine that helps them breathe when they are too weak or ill to do so on their own. Sometimes, patients struggle to come off this support, leading to complications like longer hospital stays and higher risks of infections. Researchers want to create a new method to better predict when it's safe for patients to stop using the ventilator, by looking at various factors such as how the patient interacts with the machine, their heart health, and their diaphragm function.
To participate in this study, patients need to be critically ill, have been on mechanical ventilation for more than 24 hours, and meet specific medical criteria that suggest they are ready to be weaned off the ventilator. The trial will include 126 patients, and while in the study, they will continue to receive their usual care. Researchers will gather detailed information to create a personalized score that helps doctors make better decisions about weaning patients off the ventilator, ultimately aiming to reduce complications and healthcare costs. If you or a loved one are eligible, this could contribute to improving care for future patients in similar situations.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with MV\> 24 hours.
- • Patients with orotracheal tube.
- * Patients who meet the classic criteria of weaning from the MV defined as:
- • Improvement or resolution of the cause required for MV. PaO2\> 60mmHg with FiO2≤0.4 and PEEP ≤8cm H2O. Glasgow Coma Score\> 10 Temperature \<38 ° C. Hemoglobin\> 8g / dL No need for vasoactive drugs or at doses \<5μg / kg / min Obtaining informed consent.
- Exclusion Criteria:
- • Tracheostomy patients.
- • Patients with neurological pathology with involvement of the brainstem.
About Corporacion Parc Tauli
Corporación Parc Taulí is a leading healthcare organization based in Sabadell, Spain, known for its commitment to advancing medical research and clinical excellence. With a focus on innovative healthcare solutions, the organization integrates cutting-edge technology and multidisciplinary collaboration to enhance patient outcomes. As a sponsor of clinical trials, Corporación Parc Taulí emphasizes ethical practices, rigorous scientific methodologies, and robust data management to contribute to the development of new therapies and improve healthcare standards. Their dedication to research and patient care positions them as a vital player in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sabadell, Barcelona, Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials